Please login to the form below

Not currently logged in
Email:
Password:

relugolix

This page shows the latest relugolix news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s uterine fibroids drug aces second phase III trial

AbbVie’s uterine fibroids drug aces second phase III trial

Last year, Takeda and Myovant reported positive mid-stage results with their relugolix candidate in this indication as well as endometriosis-related pain and prostate cancer.

Latest news

  • Roivant gets $1.1bn investment from Japan's SoftBank Roivant gets $1.1bn investment from Japan's SoftBank

    Axovant for example is developing a GSK cast-off for Alzheimer's disease - serotonin 5-HT6 receptor antagonist RVT-101 - through late-stage testing, while Myovant is working on relugolix, a

  • Takeda forms new women's health and cancer company Takeda forms new women's health and cancer company

    For its tie-up with Takeda, the Japanese firm has granted Myovant Sciences an exclusive, worldwide license for its prostate cancer candidate relugolix, with the exception of Asian markets. ... Andrew Plump, chief medical and scientific officer at Takeda,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics